[18F]fluorodeoxyglucose uptake by positron emission tomography for diagnosis of suspected lung cancer: Impact of verification bias

Michael S. Lauer, Sudish C. Murthy, Eugene H. Blackstone, Ikenna Okereke, Thomas W. Rice

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Background: Verification bias occurs when test findings influence the decision to perform a gold standard test. It adversely influences diagnostic test accuracy by inflating sensitivity and deflating specificity.Westudied the impact of verification bias on the estimated accuracy of a test commonly used in suspected lung cancer. Methods: We studied 534 consecutive patients referred for [18F]fluorodeoxyglucose uptake by positron emission tomography (PET). Primary outcomes were tissue diagnoses of cancer and of mediastinal lymph node metastases. A secondary outcome was 3-year mortality. We accounted for verification bias using 2 validated methods. Results: The gold standard test, namely tissue acquisition, was performed in 419 patients (78%); mediastinal lymph node sampling occurred in 301 (56%). While the 410 patients with PET-diagnosed stage I cancer or higher were more likely than patients with negative PET scan findings to undergo tissue diagnosis testing (92% vs 34%) (P

Original languageEnglish (US)
Pages (from-to)161-165
Number of pages5
JournalArchives of Internal Medicine
Volume167
Issue number2
DOIs
StatePublished - Jan 22 2007
Externally publishedYes

Fingerprint

Fluorodeoxyglucose F18
Positron-Emission Tomography
Lung Neoplasms
Mediastinal Neoplasms
Lymph Nodes
Routine Diagnostic Tests
Neoplasm Metastasis
Sensitivity and Specificity
Mortality
Neoplasms

ASJC Scopus subject areas

  • Internal Medicine

Cite this

[18F]fluorodeoxyglucose uptake by positron emission tomography for diagnosis of suspected lung cancer : Impact of verification bias. / Lauer, Michael S.; Murthy, Sudish C.; Blackstone, Eugene H.; Okereke, Ikenna; Rice, Thomas W.

In: Archives of Internal Medicine, Vol. 167, No. 2, 22.01.2007, p. 161-165.

Research output: Contribution to journalArticle

Lauer, Michael S. ; Murthy, Sudish C. ; Blackstone, Eugene H. ; Okereke, Ikenna ; Rice, Thomas W. / [18F]fluorodeoxyglucose uptake by positron emission tomography for diagnosis of suspected lung cancer : Impact of verification bias. In: Archives of Internal Medicine. 2007 ; Vol. 167, No. 2. pp. 161-165.
@article{dec4f10239a6416680ea67f99463eee8,
title = "[18F]fluorodeoxyglucose uptake by positron emission tomography for diagnosis of suspected lung cancer: Impact of verification bias",
abstract = "Background: Verification bias occurs when test findings influence the decision to perform a gold standard test. It adversely influences diagnostic test accuracy by inflating sensitivity and deflating specificity.Westudied the impact of verification bias on the estimated accuracy of a test commonly used in suspected lung cancer. Methods: We studied 534 consecutive patients referred for [18F]fluorodeoxyglucose uptake by positron emission tomography (PET). Primary outcomes were tissue diagnoses of cancer and of mediastinal lymph node metastases. A secondary outcome was 3-year mortality. We accounted for verification bias using 2 validated methods. Results: The gold standard test, namely tissue acquisition, was performed in 419 patients (78{\%}); mediastinal lymph node sampling occurred in 301 (56{\%}). While the 410 patients with PET-diagnosed stage I cancer or higher were more likely than patients with negative PET scan findings to undergo tissue diagnosis testing (92{\%} vs 34{\%}) (P",
author = "Lauer, {Michael S.} and Murthy, {Sudish C.} and Blackstone, {Eugene H.} and Ikenna Okereke and Rice, {Thomas W.}",
year = "2007",
month = "1",
day = "22",
doi = "10.1001/archinte.167.2.161",
language = "English (US)",
volume = "167",
pages = "161--165",
journal = "JAMA Internal Medicine",
issn = "2168-6106",
publisher = "American Medical Association",
number = "2",

}

TY - JOUR

T1 - [18F]fluorodeoxyglucose uptake by positron emission tomography for diagnosis of suspected lung cancer

T2 - Impact of verification bias

AU - Lauer, Michael S.

AU - Murthy, Sudish C.

AU - Blackstone, Eugene H.

AU - Okereke, Ikenna

AU - Rice, Thomas W.

PY - 2007/1/22

Y1 - 2007/1/22

N2 - Background: Verification bias occurs when test findings influence the decision to perform a gold standard test. It adversely influences diagnostic test accuracy by inflating sensitivity and deflating specificity.Westudied the impact of verification bias on the estimated accuracy of a test commonly used in suspected lung cancer. Methods: We studied 534 consecutive patients referred for [18F]fluorodeoxyglucose uptake by positron emission tomography (PET). Primary outcomes were tissue diagnoses of cancer and of mediastinal lymph node metastases. A secondary outcome was 3-year mortality. We accounted for verification bias using 2 validated methods. Results: The gold standard test, namely tissue acquisition, was performed in 419 patients (78%); mediastinal lymph node sampling occurred in 301 (56%). While the 410 patients with PET-diagnosed stage I cancer or higher were more likely than patients with negative PET scan findings to undergo tissue diagnosis testing (92% vs 34%) (P

AB - Background: Verification bias occurs when test findings influence the decision to perform a gold standard test. It adversely influences diagnostic test accuracy by inflating sensitivity and deflating specificity.Westudied the impact of verification bias on the estimated accuracy of a test commonly used in suspected lung cancer. Methods: We studied 534 consecutive patients referred for [18F]fluorodeoxyglucose uptake by positron emission tomography (PET). Primary outcomes were tissue diagnoses of cancer and of mediastinal lymph node metastases. A secondary outcome was 3-year mortality. We accounted for verification bias using 2 validated methods. Results: The gold standard test, namely tissue acquisition, was performed in 419 patients (78%); mediastinal lymph node sampling occurred in 301 (56%). While the 410 patients with PET-diagnosed stage I cancer or higher were more likely than patients with negative PET scan findings to undergo tissue diagnosis testing (92% vs 34%) (P

UR - http://www.scopus.com/inward/record.url?scp=33846458243&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846458243&partnerID=8YFLogxK

U2 - 10.1001/archinte.167.2.161

DO - 10.1001/archinte.167.2.161

M3 - Article

C2 - 17242317

AN - SCOPUS:33846458243

VL - 167

SP - 161

EP - 165

JO - JAMA Internal Medicine

JF - JAMA Internal Medicine

SN - 2168-6106

IS - 2

ER -